tert-butyl (2-methoxyethyl)glycinate | 66116-13-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: tert-butyl (2-methoxyethyl)glycinate
• 英文别名: Tert-butyl 2-[(2-methoxyethyl)amino]acetate；tert-butyl 2-(2-methoxyethylamino)acetate
• CAS: 66116-13-0
• 化学式: C₉H₁₉NO₃
• mdl: MFCD12148598
• 分子量: 189.255
• InChiKey: WZZARLZSGLWDMC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  13
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.888
• 拓扑面积：
  47.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  tert-butyl (2-methoxyethyl)glycinate 在 碘代三甲硅烷 、 水 、 三乙胺 作用下， 以 1,4-二氧六环 为溶剂， 反应 17.92h， 生成 [(3-Acetylsulfanyl-2-methyl-propionyl)-(2-methoxy-ethyl)-amino]-acetic acid
  参考文献：
  名称：

  Angiotensin-converting enzyme inhibitors. New orally active antihypertensive (mercaptoalkanoyl)- and [(acylthio)alkanoyl]glycine derivatives

  摘要：

  A variety of N-substituted (mercaptoalkanoyl)- and [(acylthio)alkanoyl]glycine derivatives was synthesized and their ability in inhibiting the activity of angiotensin-converting enzyme (ACE) was examined in vitro and in vivo. The acylthio derivatives prepared are assumed to act as prodrugs since they are much less active than the corresponding free SH compounds in vitro and can be expected to act in vivo only after conversion to the free sulfhydryl compounds. A number of these compounds are potent ACE inhibitors that lowered blood pressure in Na-deficient, conscious spontaneously hypertensive rats (SHR), a high renin model. One of the most active members of the series was (S)-N-cyclopentyl-N-[3-[(2,2-dimethyl-1-oxopropyl)thio]-2-methyl-1 -oxopropyl]glycine (REV 3659-(S), pivopril). Structure-activity relationships are discussed.

  DOI：

  10.1021/jm00379a013
• 作为产物：
  描述：

  溴乙酸叔丁酯 、 2-甲氧基乙胺 在 N,N-二异丙基乙胺 作用下， 以 乙腈 为溶剂， 反应 2.5h， 生成 tert-butyl (2-methoxyethyl)glycinate
  参考文献：
  名称：

  看到弹性蛋白：用于体内弹性蛋白成像的近红外两性离子荧光探针。

  摘要：

  弹性纤维存在于各种组织中，并对其弹性负责。到目前为止，还没有关于弹性纤维成像的700-900 nm近红外（NIR）波长范围内的光学造影剂的报道。在这里，我们报告通过基于荧光图像的筛选的近红外两性离子弹性蛋白探针ElaNIR（弹性蛋白NIR）的发现。该探针已通过各种成像方式成功地用于体外，离体和体内成像。体内荧光和光声成像显示的与年龄相关的弹性蛋白差异表明，ElaNIR可能是揭示活体模型中弹性蛋白变化的潜在便捷工具。

  DOI：

  10.1016/j.chempr.2018.02.016

文献信息

• [EN] HIGH RELAXIVITY GADOLINIUM CHELATE COMPOUNDS FOR USE IN MAGNETIC RESONANCE IMAGING<br/>[FR] COMPOSÉS DE CHÉLATE DE GADOLINIUM À RELAXIVITÉ ÉLEVÉE POUR UTILISATION DANS L'IMAGERIE PAR RÉSONANCE MAGNÉTIQUE
  申请人：BAYER PHARMA AG

  公开号：WO2018096082A1

  公开（公告）日：2018-05-31

  The present invention relates to a new class of high relaxivity extracellular gadolinium chelate complexes, to methods of preparing said compounds, and to the use of said compounds as MRI contrast agents.

  本发明涉及一种新型高弛豫性细胞外钆螯合物复合物的类别，涉及制备该类化合物的方法，以及将该类化合物用作磁共振成像对比剂。
• [EN] N-(3-(2-(4-CHLOROPHENOXY)ACETAMIDO)BICYCLO[1.1.1]PENTAN-1-YL)-2-CYCLOBUTANE-1-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ATF4 INHIBITORS FOR TREATING CANCER AND OTHER DISEASES<br/>[FR] DÉRIVÉS DE N-(3-(2-(4-CHLOROPHÉNOXY)ACÉTAMIDO)BICYCLO[1.1.1]PENTAN-1-YL)-2-CYCLOBUTANE-1-CARBOXAMIDE ET COMPOSÉS APPARENTÉS EN TANT QU'INHIBITEURS ATF4 POUR LE TRAITEMENT DU CANCER ET D'AUTRES MALADIES
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2019008506A1

  公开（公告）日：2019-01-10

  The invention is directed to substituted bridged cycloalkane derivatives. Specifically, the invention is directed to compounds according to Formula (I) wherein X, a, b, C, D, L2, L3, Y1, Y2, R2, R4, R5, R6, z2, z4, z5, and z6 are as defined herein, and salts thereof. The invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to compounds for use in methods of inhibiting the ATF4 (activating transcription factor 4) pathway and treatment of disorders associated therewith, such as e.g. cancer, neurodegenerative diseases and many other diseases, using a compound of the invention or a pharmaceutical composition comprising a compound of the invention. Preferred compounds of the invention are N-(3-(2-(4-chlorophenoxy) acetamido)bicyclo[1.1.1]pentan-l-yl)-2-cyclobutane-l-carboxamide derivatives and related compounds.

  该发明涉及替代的桥接环戊烷衍生物。具体而言，该发明涉及根据式（I）的化合物，其中X、a、b、C、D、L2、L3、Y1、Y2、R2、R4、R5、R6、z2、z4、z5和z6如本文所定义，并其盐。该发明还涉及包含该发明化合物的药物组合物。该发明还涉及用于抑制ATF4（激活转录因子4）途径和治疗相关疾病的方法的化合物，例如癌症、神经退行性疾病和许多其他疾病，使用该发明化合物或包含该发明化合物的药物组合物。该发明的优选化合物是N-(3-(2-(4-氯苯氧基)乙酰氨基)双环[1.1.1]戊烷-1-基)-2-环丁烷-1-羧酰胺衍生物及相关化合物。
• N.sup.2 -arylsulfonyl-L-argininamides and the pharmaceutically
  申请人：Mitsubishi Chemical Industries Limited

  公开号：US04093712A1

  公开（公告）日：1978-06-06

  N.sup.2 -arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof have been found to be effective as pharmaceutical agents for the inhibition and suppression of thrombosis in mammals.

  已经发现N.sup.2-芳基磺酰-L-精氨酰胺及其药学上可接受的盐对于哺乳动物的抗血栓形成和抑制具有有效的药用作用。
• N.sup.2 -arylsulfonyl-l-argininamides and the pharmaceutically
  申请人：Mitsubishi Chemical Industries Limited

  公开号：US04097472A1

  公开（公告）日：1978-06-27

  N.sup.2 -arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof have been found to be effective as pharmaceutical agents for the inhibition and suppression of thrombosis in mammals.

  N.sup.2-芳基磺酰基-L-精氨酰胺及其药学上可接受的盐被发现作为药物代理物在哺乳动物中抑制和抑制血栓形成非常有效。
• N.sup.2 -arylsulfonyl-argininamides and the pharmaceutically acceptable
  申请人：Mitsubishi Chemical Industries Limited

  公开号：US04101653A1

  公开（公告）日：1978-07-18

  N.sup.2 -arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof have been found to be effective as pharmaceutical agents for the inhibition and suppression of thrombosis in mammals.

  N.sup.2-芳基磺酰-L-精氨酰胺及其药学上可接受的盐被发现可以作为药物代理在哺乳动物中抑制和抑制血栓形成。